Company news

Oncolytics Biotech Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer

February 11, 2019

Oncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor Conference

February 4, 2019

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas

December 27, 2017

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer

December 5, 2017

Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit

December 4, 2017

Oncolytics Biotech® Establishes Scientific Advisory Board Focused on REOLYSIN® Registration Study in Metastatic Breast Cancer

November 30, 2017

Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®

November 16, 2017

Oncolytics Biotech® Inc. Announces 2017 Third Quarter Results

November 8, 2017

Oncolytics Biotech® Appoints Deborah Brown to Board of Directors

November 2, 2017

Oncolytics Biotech® to Present at the 2017 BIO Investor Forum

October 11, 2017

Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference

September 19, 2017

Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer

September 18, 2017

Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study

September 14, 2017

Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress

September 11, 2017

Oncolytics Biotech® Inc. Announces 2017 Second Quarter Results

August 3, 2017

Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference

August 1, 2017

Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress

July 26, 2017

Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.

June 29, 2017

Oncolytics Biotech® Inc. Opens U.S. Based Office in San Diego

June 27, 2017

Oncolytics Biotech® Announces Closing of Public Offering of Units

June 1, 2017

Oncolytics Biotech® Prices Public Offering of Units

May 24, 2017

Oncolytics Biotech® Announces Proposed Public Offering

May 23, 2017

Oncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017

May 23, 2017

Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers

May 17, 2017

Oncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in Metastatic Breast Cancer

May 8, 2017

Oncolytics Biotech® Inc. Announces 2017 First Quarter Results

May 5, 2017

Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders

May 4, 2017

Oncolytics Biotech® Inc. Announces Details of 2017 Annual Meeting of Shareholders

April 27, 2017

Oncolytics Biotech® Inc. to Present at the Sixth Annual Bloom Burton & Co. Healthcare Investor Conference

April 26, 2017

Oncolytics Biotech® Inc. Announces Registration Pathway and Clinical Development Plan

April 12, 2017

Oncolytics Biotech® Inc.'s REOLYSIN® More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer

April 5, 2017

Oncolytics Biotech® Inc.'s REOLYSIN® Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast Cancer

March 31, 2017

Oncolytics Biotech® Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN® in Combination with Imnovid® or Revlimid® in Patients with Myeloma

March 16, 2017

Oncolytics Biotech® Inc. Announces 2016 Year-End Results

March 10, 2017

Oncolytics Biotech® Inc. Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting

March 2, 2017

Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO

January 19, 2017

Oncolytics Biotech® Inc. Announces Change to Board of Directors

December 6, 2016

Oncolytics Biotech® Inc. Collaborators Present Initial Results from REO 019 Study in Multiple Myeloma Combining REOLYSIN®, Bortezomib and Dexamethasone at the ASH Annual Meeting

December 6, 2016

Oncolytics Biotech® Inc. Announces Appointment of New Chief Medical Officer

November 10, 2016

Oncolytics Biotech® Inc. Announces 2016 Third Quarter Results

November 3, 2016

Media Advisory - Oncolytics Biotech® Inc. Announces Management Team Changes

November 2, 2016

Media Advisory - Oncolytics Biotech® Inc. Announces Participation in the 2016 BIO Investor Forum

October 18, 2016

Media Advisory - Oncolytics Biotech® Inc. Announces Participation in the 4th Annual Immuno-Oncology Summit

August 30, 2016

MEDIA ADVISORY - Oncolytics Biotech® Inc. Announces Participation in the Canaccord Genuity 36th Annual Growth Conference

August 10, 2016

Oncolytics Biotech® Inc. Reports Additional Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer

August 10, 2016

Oncolytics Biotech® Inc. Announces 2016 Second Quarter Results

August 4, 2016

Oncolytics Biotech® Inc. Announces Phase 2 Study in Female Patients with Colorectal Cancer Metastatic to the Liver

June 29, 2016

Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN® in Colorectal Cancer

May 19, 2016

Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer

May 19, 2016

Oncolytics Biotech® Inc. Announces 2016 First Quarter Results

May 6, 2016

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.